SEARCH

SEARCH BY CITATION

References

  • 1
    Eiermann W , Paepke S, Appfelstaedt Jet al.Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001; 12: 152732.
  • 2
    Ellis MJ , Coop A, Singh Bet al.Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001; 19: 380816.
  • 3
    Semiglazov V , Semiglazov VV, Ivanov VGet al.Anastrozole (A) vs tamoxifen (T) vs combine (A + T) as neoadjuvant endocrine therapy of postmenopausal breast cancer patients. Breast 2003; 12: 3987, abs 3538.
  • 4
    Huober J , Krainick-Strobel U, Kurek R, Wallwiener D. Neoadjuvant endocrine therapy in primary breast cancer. Clin Breast Cancer 2004; 5: 3417.
  • 5
    Dixon JM , Renshaw L, Bellamy C, Stuart M, Hoctin-Boes G, Miller WR. The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. Clin Cancer Res 2000; 6: 222935.
  • 6
    Ellis MJ , Tao Y, Luo Jet al.Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 2008; 100: 13808.
  • 7
    Cataliotti L , Buzdar AU, Noguchi Set al.Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the pre-operative “Arimidex” compared to tamoxifen (PROACT) trial. Cancer 2006; 106: 2095103.
  • 8
    The ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005; 365: 602.
  • 9
    Jakesz R , Jonat W, Gnant Met al.Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366: 45562.
  • 10
    Kurosumi M , Akiyama F, Iwase T, Motomura K, Okazaki M, Tsuda H. Histopathological criteria for assessment of therapeutic response in breast cancer. Breast Cancer 2001; 8: 12.
  • 11
    Kurosumi M , Takatsuka Y, Watanabe Tet al.Histopathological assessment of anastrozole and tamoxifen as preoperative (neoadjuvant) treatment in postmenopausal Japanese women with hormone receptor-positive breast cancer in the PROACT trial. J Cancer Res Clin Oncol 2008; 134: 71522.
  • 12
    Cuzick J , Sestak I, Baum Met al.Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010; 11: 113541.
  • 13
    Goetz MP , Rae JM, Suman VJet al.Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005; 23: 93128.
  • 14
    Lim HS , Ju Lee H, Seok Lee K, Sook Lee E, Jang IJ, Ro J. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol 2007; 25: 383745.
  • 15
    Kiyotani K , Mushiroda T, Imamura CKet al.Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol 2010; 28: 128793.
  • 16
    Shimizu T , Ochiai H, Asell Fet al.Bioinformatics research on inter-racial difference in drug metabolism I. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19. Drug Metab Pharmacokinet 2003; 18: 4870.
  • 17
    de Souza JA , Olopade OI. CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine. Semin Oncol 2011; 38: 26373.
  • 18
    Fisher B , Brown A, Mamounas Eet al.Effect of preoperative chemotherapy on local-regional disease in women with operative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997; 15: 248393.
  • 19
    Bear HD , Anderson S, Brown Aet al.The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003; 21: 416574.
  • 20
    Dellapasqua S , Colleoni M. Letrozole. Expert Opin Drug Metab Toxicol 2010; 6: 2519.
  • 21
    The BIG 1-98 Collaborative Group. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009; 361: 76676.